Tuberous Sclerosis Complex
40
6
12
21
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Published Results
13 trials with published results (33%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
2.5%
1 terminated out of 40 trials
95.5%
+8.9% vs benchmark
20%
8 trials in Phase 3/4
62%
13 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (40)
A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
Feasibility of [11C]Acetate-PET in LAM and TSC
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
Predicting Epileptogenic Tubers in Patients with Tuberous Sclerosis Complex
The Effectiveness and Safety of Resective Epilepsy Surgery for TRE
The Effectiveness and Safety of Vagus Nerve Stimulation for TRE
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
Acceptance and Commitment Therapy in Tuberous Sclerosis Complex
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France